559 related articles for article (PubMed ID: 7909557)
1. Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors.
Shannon HE; Bymaster FP; Calligaro DO; Greenwood B; Mitch CH; Sawyer BD; Ward JS; Wong DT; Olesen PH; Sheardown MJ; Swedberg MD; Suzdak PD; Sauerberg P
J Pharmacol Exp Ther; 1994 Apr; 269(1):271-81. PubMed ID: 7909557
[TBL] [Abstract][Full Text] [Related]
2. Neurochemical effects of the M1 muscarinic agonist xanomeline (LY246708/NNC11-0232).
Bymaster FP; Wong DT; Mitch CH; Ward JS; Calligaro DO; Schoepp DD; Shannon HE; Sheardown MJ; Olesen PH; Suzdak PD; Swedberg MD; Sauerberg P
J Pharmacol Exp Ther; 1994 Apr; 269(1):282-9. PubMed ID: 7909558
[TBL] [Abstract][Full Text] [Related]
3. Pharmacology of butylthio[2.2.2] (LY297802/NNC11-1053): a novel analgesic with mixed muscarinic receptor agonist and antagonist activity.
Shannon HE; Sheardown MJ; Bymaster FP; Calligaro DO; Delapp NW; Gidda J; Mitch CH; Sawyer BD; Stengel PW; Ward JS; Wong DT; Olesen PH; Suzdak PD; Sauerberg P; Swedberg MD
J Pharmacol Exp Ther; 1997 May; 281(2):884-94. PubMed ID: 9152398
[TBL] [Abstract][Full Text] [Related]
4. M1 receptor agonist activity is not a requirement for muscarinic antinociception.
Sheardown MJ; Shannon HE; Swedberg MD; Suzdak PD; Bymaster FP; Olesen PH; Mitch CH; Ward JS; Sauerberg P
J Pharmacol Exp Ther; 1997 May; 281(2):868-75. PubMed ID: 9152396
[TBL] [Abstract][Full Text] [Related]
5. Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors.
Watson J; Brough S; Coldwell MC; Gager T; Ho M; Hunter AJ; Jerman J; Middlemiss DN; Riley GJ; Brown AM
Br J Pharmacol; 1998 Dec; 125(7):1413-20. PubMed ID: 9884068
[TBL] [Abstract][Full Text] [Related]
6. Novel functional M1 selective muscarinic agonists. Synthesis and structure-activity relationships of 3-(1,2,5-thiadiazolyl)-1,2,5,6-tetrahydro-1-methylpyridines .
Sauerberg P; Olesen PH; Nielsen S; Treppendahl S; Sheardown MJ; Honoré T; Mitch CH; Ward JS; Pike AJ; Bymaster FP
J Med Chem; 1992 Jun; 35(12):2274-83. PubMed ID: 1613751
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological analysis of the novel mode of interaction between xanomeline and the M1 muscarinic acetylcholine receptor.
Christopoulos A; Parsons AM; El-Fakahany EE
J Pharmacol Exp Ther; 1999 Jun; 289(3):1220-8. PubMed ID: 10336509
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological characterisation of the enantiomers of BM-5, a muscarinic partial agonist with opposed enantioselectivity between affinity and efficacy.
Sundquist S; Modiri AR; Nilsson BM; Hacksell U; Gillberg PG; Nilvebrant L
Pharmacol Toxicol; 2000 Jan; 86(1):44-50. PubMed ID: 10720106
[TBL] [Abstract][Full Text] [Related]
9. Wash-resistantly bound xanomeline inhibits acetylcholine release by persistent activation of presynaptic M(2) and M(4) muscarinic receptors in rat brain.
Machová E; Jakubík J; El-Fakahany EE; Dolezal V
J Pharmacol Exp Ther; 2007 Jul; 322(1):316-23. PubMed ID: 17446301
[TBL] [Abstract][Full Text] [Related]
10. Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effects.
Bymaster FP; Carter PA; Peters SC; Zhang W; Ward JS; Mitch CH; Calligaro DO; Whitesitt CA; DeLapp N; Shannon HE; Rimvall K; Jeppesen L; Sheardown MJ; Fink-Jensen A; Sauerberg P
Brain Res; 1998 Jun; 795(1-2):179-90. PubMed ID: 9622623
[TBL] [Abstract][Full Text] [Related]
11. Low-affinity M(2) receptor binding state mediates mouse atrial bradycardia: comparative effects of carbamylcholine and the M(1) receptor agonists sabcomeline and xanomeline.
Stengel PW; Cohen ML
J Pharmacol Exp Ther; 2001 Mar; 296(3):818-24. PubMed ID: 11181912
[TBL] [Abstract][Full Text] [Related]
12. Distinct functional muscarinic receptors in guinea-pig gallbladder, ileum and atria.
Karaalp A; Akici A; Akbulut H; Ulusoy NB; Oktay S
Pharmacol Res; 1999 May; 39(5):389-95. PubMed ID: 10328997
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological properties of (2R)-N-[1-(6-aminopyridin-2-ylmethyl)piperidin-4-yl]-2-[(1R)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamide: a novel mucarinic antagonist with M(2)-sparing antagonistic activity.
Hirose H; Aoki I; Kimura T; Fujikawa T; Numazawa T; Sasaki K; Sato A; Hasegawa T; Nishikibe M; Mitsuya M; Ohtake N; Mase T; Noguchi K
J Pharmacol Exp Ther; 2001 May; 297(2):790-7. PubMed ID: 11303071
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the muscarinic receptor subtype(s) mediating contraction of the guinea-pig lung strip and inhibition of acetylcholine release in the guinea-pig trachea with the selective muscarinic receptor antagonist tripitramine.
Roffel AF; Davids JH; Elzinga CR; Wolf D; Zaagsma J; Kilbinger H
Br J Pharmacol; 1997 Sep; 122(1):133-41. PubMed ID: 9298539
[TBL] [Abstract][Full Text] [Related]
15. Effects of imidafenacin (KRP-197/ONO-8025), a new anti-cholinergic agent, on muscarinic acetylcholine receptors. High affinities for M3 and M1 receptor subtypes and selectivity for urinary bladder over salivary gland.
Kobayashi F; Yageta Y; Segawa M; Matsuzawa S
Arzneimittelforschung; 2007; 57(2):92-100. PubMed ID: 17396619
[TBL] [Abstract][Full Text] [Related]
16. (+/-)-Terodiline: an M1-selective muscarinic receptor antagonist. In vivo effects at muscarinic receptors mediating urinary bladder contraction, mydriasis and salivary secretion.
Noronha-Blob L; Prosser JC; Sturm BL; Lowe VC; Enna SJ
Eur J Pharmacol; 1991 Aug; 201(2-3):135-42. PubMed ID: 1724648
[TBL] [Abstract][Full Text] [Related]
17. Novel functional M1 selective muscarinic agonists. 2. Synthesis and structure-activity relationships of 3-pyrazinyl-1,2,5,6-tetrahydro-1-methylpyridines. Construction of a molecular model for the M1 pharmacophore.
Ward JS; Merritt L; Klimkowski VJ; Lamb ML; Mitch CH; Bymaster FP; Sawyer B; Shannon HE; Olesen PH; Honoré T
J Med Chem; 1992 Oct; 35(22):4011-9. PubMed ID: 1433209
[TBL] [Abstract][Full Text] [Related]
18. Muscarinic M1 receptor agonist actions of muscarinic receptor agonists in rabbit vas deferens.
Shannon HE; Sawyer BD; Bemis KG; Bymaster FP; Health I; Mitch CH; Ward JS
Eur J Pharmacol; 1993 Feb; 232(1):47-57. PubMed ID: 8458395
[TBL] [Abstract][Full Text] [Related]
19. Persistent binding and functional antagonism by xanomeline at the muscarinic M5 receptor.
Grant MK; El-Fakahany EE
J Pharmacol Exp Ther; 2005 Oct; 315(1):313-9. PubMed ID: 16002459
[TBL] [Abstract][Full Text] [Related]
20. New analogues of oxotremorine and oxotremorine-M: estimation of their in vitro affinity and efficacy at muscarinic receptor subtypes.
Barocelli E; Ballabeni V; Bertoni S; Dallanoce C; De Amici M; De Micheli C; Impicciatore M
Life Sci; 2000 Jun; 67(6):717-23. PubMed ID: 12659177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
